In summary, the ALGONQUIN trial demonstrated that the combination of belamaf plus Pd resulted in promising efficacy for patients with relapsed MM, comparable to the anti-BCMA bispecific antibodies and ide-cel CAR T cell therapy and an improvement over other Pd-based combinations. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.